^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

19P - PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study

Published date:
05/23/2020
Excerpt:
PIK3CA mutation showed a favorable prognostic impact in the subgroup of patients owing to the PAM50 HER2-enriched subtype (n=232): 5-yr DFS 91.8% vs 76.1% for PIK3CA mutated and wild-type patients (log-rank p=0.049; HR 0.46 95% CI 0.21-1.02)....Within the HER2-enriched molecular subtype, PIK3CA mutated patients showed better DFS as compared to PIK3CA wild-type patients.
Trial ID: